Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications.

As FGFR inhibitors may soon become the new alternative to standard chemotherapy in FGFR-mutated cholangiocarcinoma, accurate molecular testing and monitoring of acquired resistance mechanisms will be essential. The possible application of FGFR inhibitors in first-line treatment, as well as in combination to current standard treatments, remains the next step to be taken.